JP2018509388A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509388A5
JP2018509388A5 JP2017539419A JP2017539419A JP2018509388A5 JP 2018509388 A5 JP2018509388 A5 JP 2018509388A5 JP 2017539419 A JP2017539419 A JP 2017539419A JP 2017539419 A JP2017539419 A JP 2017539419A JP 2018509388 A5 JP2018509388 A5 JP 2018509388A5
Authority
JP
Japan
Prior art keywords
composition
polypeptide
subject
hemolysis
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017539419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509388A (ja
JP6640229B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2015/035473 external-priority patent/WO2015191951A2/en
Application filed filed Critical
Priority claimed from PCT/US2016/015412 external-priority patent/WO2016123371A1/en
Publication of JP2018509388A publication Critical patent/JP2018509388A/ja
Publication of JP2018509388A5 publication Critical patent/JP2018509388A5/ja
Priority to JP2019233666A priority Critical patent/JP6915034B2/ja
Application granted granted Critical
Publication of JP6640229B2 publication Critical patent/JP6640229B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017539419A 2015-01-28 2016-01-28 補体活性の変調剤 Active JP6640229B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019233666A JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562108772P 2015-01-28 2015-01-28
US62/108,772 2015-01-28
USPCT/US2015/035473 2015-06-12
PCT/US2015/035473 WO2015191951A2 (en) 2014-06-12 2015-06-12 Modulation of complement activity
US201562185298P 2015-06-26 2015-06-26
US62/185,298 2015-06-26
PCT/US2016/015412 WO2016123371A1 (en) 2015-01-28 2016-01-28 Modulators of complement activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233666A Division JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Publications (3)

Publication Number Publication Date
JP2018509388A JP2018509388A (ja) 2018-04-05
JP2018509388A5 true JP2018509388A5 (enExample) 2019-03-07
JP6640229B2 JP6640229B2 (ja) 2020-02-05

Family

ID=56544343

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017539419A Active JP6640229B2 (ja) 2015-01-28 2016-01-28 補体活性の変調剤
JP2019233666A Active JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019233666A Active JP6915034B2 (ja) 2015-01-28 2019-12-25 補体活性の変調剤

Country Status (14)

Country Link
US (6) US9937222B2 (enExample)
EP (2) EP3250230B9 (enExample)
JP (2) JP6640229B2 (enExample)
CY (1) CY1124761T1 (enExample)
ES (1) ES2900998T3 (enExample)
HR (1) HRP20211824T1 (enExample)
HU (1) HUE056613T2 (enExample)
LT (1) LT3250230T (enExample)
PL (1) PL3250230T3 (enExample)
PT (1) PT3250230T (enExample)
RS (1) RS62630B9 (enExample)
SI (1) SI3250230T1 (enExample)
SM (1) SMT202100688T1 (enExample)
WO (1) WO2016123371A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211561T8 (hr) 2014-06-12 2022-03-04 Ra Pharmaceuticals, Inc. Modulacija aktivnosti komplementa
SMT202100688T1 (it) 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
PT3685847T (pt) 2015-12-16 2023-03-14 Ra Pharmaceuticals Inc Moduladores de atividade de complemento
MX2019006527A (es) * 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
KR20190138650A (ko) * 2017-04-21 2019-12-13 볼루션 이뮤노 파마슈티컬스 에스에이 반흔성 안구 염증성 장애의 치료를 위한 코버신
AU2018253962B2 (en) 2017-04-21 2024-12-05 Volution Immuno Pharmaceuticals Sa Coversin for the treatment of autoimmune blistering diseases
JP2022508952A (ja) 2018-10-22 2022-01-19 ラ ファーマシューティカルズ インコーポレイテッド ジルコプランによる神経疾患治療
ES2973767T3 (es) 2019-06-04 2024-06-24 Ra Pharmaceuticals Inc Tratamiento de enfermedades inflamatorias con inhibidores del complemento
JP6773930B1 (ja) 2019-08-09 2020-10-21 住友化学株式会社 液晶ポリエステル樹脂成形体、液晶ポリエステル樹脂ペレット、及び液晶ポリエステル樹脂ペレットの製造方法
CA3150594A1 (en) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Neurological disease treatment with complement inhibitors
WO2022177635A2 (en) * 2021-02-22 2022-08-25 Ra Pharmaceuticals, Inc. Compositions and methods for microbial disease treatment

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271068A (en) 1968-05-10 1981-06-02 Ciba-Geigy Corporation Process for the manufacture of cystine-containing peptides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033940A (en) 1975-11-12 1977-07-05 Armour Pharmaceutical Company Cyclization of peptides
US4216141A (en) 1978-07-19 1980-08-05 The Salk Institute For Biological Studies Method for cyclization of peptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5371109A (en) 1986-07-01 1994-12-06 Drilletten Ab Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5585353A (en) 1990-02-02 1996-12-17 The Rockefeller University Antibiotic peptides containing D-amino acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
AU684510B2 (en) 1993-05-28 1997-12-18 Chiron Corporation Method for selection of biologically active peptide sequences
EP0710243B1 (en) 1993-06-29 2000-06-14 Ferring B.V. Synthesis of cyclic peptides
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5834318A (en) 1995-05-10 1998-11-10 Bayer Corporation Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE69730157T2 (de) 1996-10-17 2005-07-28 Mitsubishi Chemical Corp. Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US5922680A (en) 1996-10-23 1999-07-13 Ferring, B.V. Stabilized composition for oral administration of peptides
EP1712623B1 (en) 1997-01-21 2011-10-19 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP0985039B1 (en) 1997-06-12 2008-02-20 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP0896001A1 (en) 1997-08-08 1999-02-10 Daicel Chemical Industries, Ltd. Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
JP4430235B2 (ja) 1998-08-07 2010-03-10 エミスフェアー・テクノロジーズ・インク 活性剤のデリバリーのための化合物及び組成物
WO2000021559A2 (en) 1998-10-09 2000-04-20 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6962781B1 (en) 2000-05-19 2005-11-08 Proteonova, Inc. In vitro evolution of nucleic acids and encoded polypeptide
US7244701B2 (en) 2000-06-16 2007-07-17 Zealand Phama A/S Diuretic peptide conjugate
US8329169B2 (en) 2003-05-15 2012-12-11 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis
EP1667702A2 (en) 2003-09-10 2006-06-14 Baxter International Inc., Baxter Healthcare Corp. Peptides that inhibit complement activation
JP4994039B2 (ja) 2003-11-26 2012-08-08 スパーナス ファーマシューティカルズ インコーポレイテッド 脂溶性または疎水性化合物の送達に有用なミセル系
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060027059A1 (en) 2004-08-09 2006-02-09 Chih-Ching Hsien Extendable handle device
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
PL1844337T3 (pl) 2005-01-24 2013-12-31 Pepscan Systems Bv Związki wiążące, związki immunogenne i peptydomimetyki
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
CA2610340C (en) 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
PL2359834T3 (pl) 2006-03-15 2017-09-29 Alexion Pharmaceuticals, Inc. Leczenie pacjentów cierpiących na nocną napadową hemoglobinurię z użyciem inhibitora dopełniacza
EP1876183A1 (en) 2006-07-04 2008-01-09 Technische Universität München Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins
WO2008044928A1 (en) 2006-10-10 2008-04-17 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
US7736860B2 (en) 2006-11-09 2010-06-15 Univeristy Of Massachusetts Methods of identifying compounds for the treatment of sterile inflammation
EP2121016A1 (en) 2007-03-06 2009-11-25 Novo Nordisk A/S Modulation of complement system activation for treatment of bleeding-related inflammation
EA200901211A1 (ru) 2007-03-22 2010-04-30 Новартис Аг Антигены белка с5 и их применение
US20100015139A1 (en) 2008-07-10 2010-01-21 Rekha Bansal METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF
WO2008137236A2 (en) 2007-04-30 2008-11-13 Alcon Research, Ltd. Treatment of age-related macular degeneration using inhibitors of complement factor d
CN101809034B (zh) 2007-06-07 2015-07-08 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
WO2009014633A1 (en) 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
CA2701470A1 (en) 2007-10-02 2009-04-09 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels
WO2009067191A2 (en) 2007-11-16 2009-05-28 The General Hospital Corporation Methods and compositions for the treatment of hepatitis c virus (hcv) infection
WO2009121065A2 (en) 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010014830A2 (en) 2008-07-30 2010-02-04 Cosmix Therapeutics Llc Peptide therapeutics that bind vegf and methods of use thereof
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
US9447176B2 (en) 2008-11-10 2016-09-20 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CN102781471B (zh) 2009-10-16 2016-10-12 奥默罗斯公司 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
CN111560060A (zh) 2009-12-16 2020-08-21 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
US9172511B2 (en) 2009-12-24 2015-10-27 Samsung Electronics Co., Ltd. Apparatus and method of communicating automatic repeat request (ARQ) feedback in a wireless communication network
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011137363A1 (en) 2010-04-30 2011-11-03 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
CA2832187C (en) 2011-04-08 2017-10-10 Gregory A. Demopulos Methods for treating conditions associated with masp-2 dependent complement activation
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN102321170B (zh) 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
US20140296147A1 (en) 2011-10-06 2014-10-02 The Medicines Company Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010
HRP20190522T1 (hr) 2012-02-20 2019-05-03 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi koji se vežu za humani komplement c5
AU2013222343B2 (en) * 2012-02-21 2016-10-06 Chevron U.S.A. Inc. System and method for measuring well flow rate
US20130246083A1 (en) 2012-03-16 2013-09-19 Alexion Pharmaceuticals, Inc. Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9579360B2 (en) 2012-06-20 2017-02-28 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20130345257A1 (en) 2012-06-26 2013-12-26 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
WO2014078622A1 (en) 2012-11-15 2014-05-22 The Brigham And Women's Hospital, Inc. Method and system for diagnosing and treating preeclampsia
US9700633B2 (en) 2013-01-28 2017-07-11 Jenkem Technology Co., Ltd., Tianjin Branch Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
US20140234275A1 (en) 2013-02-15 2014-08-21 Jason Williams Method for treating als via the increased production of factor h
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
SG11201607740TA (en) 2014-03-20 2016-10-28 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
HRP20211561T8 (hr) * 2014-06-12 2022-03-04 Ra Pharmaceuticals, Inc. Modulacija aktivnosti komplementa
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
GB2541835B (en) 2015-01-21 2018-09-12 Pacira Pharmaceuticals Inc Multivesicular liposome formulations of tranexamic acid
SMT202100688T1 (it) * 2015-01-28 2022-01-10 Ra Pharmaceuticals Inc Modulatori di attività del complemento
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
PT3685847T (pt) 2015-12-16 2023-03-14 Ra Pharmaceuticals Inc Moduladores de atividade de complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
US20200282024A1 (en) 2017-09-11 2020-09-10 Ra Pharmaceuticals, Inc. Formulations for compound delivery
US20210000927A1 (en) 2017-12-04 2021-01-07 Ra Pharmaceuticals, Inc. Modulators of complement activity
CA3131927A1 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
CN113710230A (zh) 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法

Similar Documents

Publication Publication Date Title
JP2018509388A5 (enExample)
PH12020500555A1 (en) Esketamine for the treatment of depression
JP2017158561A5 (enExample)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2015517488A5 (enExample)
EP4233861A3 (en) Compositions for treatment of essential tremor
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
JP2015518818A5 (enExample)
JP2013542919A5 (enExample)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
BR112015010396A2 (pt) terapia de combinação
SG10201901242PA (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
JP2011225596A5 (enExample)
PH12014501620A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
WO2013188210A3 (en) Treatment of side effects associated with parkinson's disease treatments
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
JP2018529666A5 (enExample)
JP2017519762A5 (enExample)
JP2016512247A5 (enExample)
ZA202106768B (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria
MX2015014668A (es) Angiotensinas en la distrofia muscular.